Replicor
Manufacturing · Canada · 1-10 Employees
View Company Info for Free
Overview
Headquarters
6100 Av Royalmount, Montreal, Quebec, H4...Phone Number
(514) 733-1998Website
www.replicor.comRevenue
<$5 MillionIndustry
About Replicor
Replicor is a clinical-stage biopharmaceutical company focused on developing NUCLEIC ACID POLYMERS (NAPs) for the treatment of chronic hepatitis B (HBV) and hepatitis delta (HDV). Their lead candidate, REP 2139, has demonstrated significant antiviral effects and safety in clinical studies, targeting both viruses through innovative combination therapies. The company aims to provide a cure for HBV and HDV, showcasing unique properties of NAPs that enhance their efficacy while minimizing side effects. Replicor's intended clients include patients suffering from chronic hepatitis infections and healthcare providers seeking advanced treatment options.Explore more
Replicor Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Compare Similar Companies to Replicor
Compare insights from companies similar to Replicor, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Replicor Tech Stack
A closer look at the technologies used by Replicor
Top Manufacturing Companies
Top companies in New Zealand by revenue
Top companies in United Kingdom by revenue
Frequently Asked Questions Regarding Replicor
Sign Up For FreeTo access detailed company insights
Replicor is a clinical-stage biopharmaceutical company focused on developing NUCLEIC ACID POLYMERS (NAPs) for the treatment of chronic hepatitis B (HBV) and hepatitis delta (HDV). Their lead candidate, REP 2139, has demonstrated significant antiviral effects and safety in clinical studies, targeting both viruses through innovative combination thera... Read More
